These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25388285)

  • 21. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.
    Ma J; Urba WJ; Si L; Wang Y; Fox BA; Hu HM
    Eur J Immunol; 2003 Aug; 33(8):2123-32. PubMed ID: 12884286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
    Li B; VanRoey MJ; Jooss K
    Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using lymph node swelling as a potential biomarker for successful vaccination.
    Brewer KD; DeBay DR; Dude I; Davis C; Lake K; Parsons C; Rajagopalan R; Weir G; Stanford MM; Mansour M; Bowen CV
    Oncotarget; 2016 Jun; 7(24):35655-35669. PubMed ID: 27232944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.
    Muraoka D; Harada N; Hayashi T; Tahara Y; Momose F; Sawada S; Mukai SA; Akiyoshi K; Shiku H
    ACS Nano; 2014 Sep; 8(9):9209-18. PubMed ID: 25180962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
    Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
    Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11.
    Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y
    Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
    Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
    J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node.
    Cheng L; Wang Y; Huang L
    Mol Ther; 2017 Jul; 25(7):1665-1675. PubMed ID: 28284981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses.
    Sheng S; Zhang H; Li X; Chen J; Wang P; Liang Y; Li C; Li H; Pan N; Bao X; Liu M; Zhao L; Li X; Guan P; Wang X
    J Nanobiotechnology; 2024 May; 22(1):267. PubMed ID: 38764014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.
    Pantel A; Cheong C; Dandamudi D; Shrestha E; Mehandru S; Brane L; Ruane D; Teixeira A; Bozzacco L; Steinman RM; Longhi MP
    Eur J Immunol; 2012 Jan; 42(1):101-9. PubMed ID: 22002164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
    Neal ZC; Bates MK; Albertini MR; Herweijer H
    Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.